Skip to main
EYEN
EYEN logo

Eyenovia (EYEN) Stock Forecast & Price Target

Eyenovia (EYEN) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Eyenovia Inc. is strategically positioned within the ophthalmic sector, leveraging its proprietary array print (MAP) platform technology and the user-filled Optejet system, which enhances the precision and delivery of ophthalmic therapies. The approval and market presence of Mydcombi highlights the effectiveness of the Optejet's delivery method, setting a foundation for potential future growth through additional product approvals and partnerships in untreated conditions such as dry eye disease. Despite a shift in rating and price target, the underlying developments, including ongoing collaborations and the streamlined focus on the Optejet, suggest a favorable outlook for Eyenovia's innovations in smart ophthalmic therapies.

Bears say

Eyenovia Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to the setbacks in product development and commercial viability. Specifically, the failure of the Phase 3 CHAPERONE trial, which aimed to use the Optejet for delivering MicroPineatropine, has raised concerns regarding the company's ability to achieve peak commercial revenue estimates and secure necessary capital resources to support ongoing operations. Furthermore, potential execution challenges related to the pandemic have exacerbated uncertainties regarding program development and commercialization, emphasizing the need for strategic alternatives to enhance the utilization of its delivery technology.

Eyenovia (EYEN) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eyenovia and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eyenovia (EYEN) Forecast

Analysts have given Eyenovia (EYEN) a Buy based on their latest research and market trends.

According to 4 analysts, Eyenovia (EYEN) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eyenovia (EYEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.